RYTM – Rhythm Pharmaceuticals Inc.
RYTM — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
14.42
Margin Of Safety %
Put/Call OI Ratio
0.35
EPS Next Q Diff
-0.09
EPS Last/This Y
-0.15
EPS This/Next Y
2.61
Price
115.68
Target Price
141.53
Analyst Recom
1.12
Performance Q
20.16
Upside
-195.0%
Beta
1.98
Ticker: RYTM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | RYTM | 107.6 | 0.49 | 0.17 | 3329 |
| 2026-07-14 | RYTM | 109.81 | 0.48 | 0.67 | 3335 |
| 2026-07-15 | RYTM | 109.41 | 0.49 | 0.60 | 3340 |
| 2026-07-16 | RYTM | 106.08 | 0.49 | 0.80 | 3345 |
| 2026-07-17 | RYTM | 106.41 | 0.47 | 0.14 | 3313 |
| 2026-07-20 | RYTM | 104.61 | 0.50 | 1.43 | 2598 |
| 2026-07-21 | RYTM | 105.68 | 0.50 | 0.00 | 2612 |
| 2026-07-22 | RYTM | 104.07 | 0.49 | 0.67 | 2636 |
| 2026-07-23 | RYTM | 102.78 | 0.49 | 0.80 | 2640 |
| 2026-07-24 | RYTM | 102.12 | 0.49 | 999.99 | 2648 |
| 2026-07-27 | RYTM | 106.41 | 0.50 | 0.00 | 2651 |
| 2026-07-28 | RYTM | 108.1 | 0.49 | 0.38 | 2685 |
| 2026-07-29 | RYTM | 106.53 | 0.49 | 4.50 | 2697 |
| 2026-07-30 | RYTM | 105.7 | 0.49 | 0.00 | 2706 |
| 2026-07-31 | RYTM | 99.14 | 0.47 | 0.43 | 2801 |
| 2026-08-03 | RYTM | 102.81 | 0.46 | 0.01 | 2936 |
| 2026-08-04 | RYTM | 106.7 | 0.35 | 0.01 | 3549 |
| 2026-08-05 | RYTM | 110.69 | 0.33 | 0.00 | 3694 |
| 2026-08-07 | RYTM | 115.68 | 0.35 | 1.70 | 3610 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | RYTM | 107.59 | -12.3 | - | -3.25 |
| 2026-07-14 | RYTM | 109.83 | -12.3 | - | -3.25 |
| 2026-07-15 | RYTM | 109.61 | -12.1 | - | -3.24 |
| 2026-07-16 | RYTM | 106.04 | -12.1 | - | -3.24 |
| 2026-07-17 | RYTM | 106.51 | -11.9 | - | -3.24 |
| 2026-07-20 | RYTM | 104.64 | -11.9 | - | -3.24 |
| 2026-07-21 | RYTM | 106.56 | -11.9 | - | -3.24 |
| 2026-07-22 | RYTM | 104.04 | -11.9 | - | -3.24 |
| 2026-07-23 | RYTM | 102.75 | -11.9 | - | -3.24 |
| 2026-07-24 | RYTM | 102.24 | -11.9 | - | -3.27 |
| 2026-07-27 | RYTM | 106.15 | -11.9 | - | -3.27 |
| 2026-07-28 | RYTM | 108.06 | -12.3 | - | -3.29 |
| 2026-07-29 | RYTM | 106.52 | -12.3 | - | -3.29 |
| 2026-07-30 | RYTM | 105.81 | -12.3 | - | -3.29 |
| 2026-07-31 | RYTM | 99.14 | -11.0 | - | -3.26 |
| 2026-08-03 | RYTM | 102.70 | -11.0 | - | -3.26 |
| 2026-08-04 | RYTM | 102.70 | -11.0 | - | -3.26 |
| 2026-08-05 | RYTM | 110.57 | -11.0 | - | -3.26 |
| 2026-08-06 | RYTM | 112.10 | -11.0 | - | -3.26 |
| 2026-08-07 | RYTM | 115.68 | -11.0 | - | -3.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | RYTM | -3.04 | 0.59 | 14.56 |
| 2026-07-14 | RYTM | -3.04 | 0.59 | 14.56 |
| 2026-07-15 | RYTM | -3.04 | 0.59 | 14.56 |
| 2026-07-16 | RYTM | -3.04 | 0.59 | 14.56 |
| 2026-07-17 | RYTM | -3.04 | 0.59 | 14.56 |
| 2026-07-20 | RYTM | -3.04 | 0.61 | 14.56 |
| 2026-07-21 | RYTM | -3.05 | 0.61 | 14.56 |
| 2026-07-22 | RYTM | -3.05 | 0.61 | 14.56 |
| 2026-07-23 | RYTM | -3.05 | 0.61 | 14.56 |
| 2026-07-24 | RYTM | -3.05 | 0.61 | 14.56 |
| 2026-07-27 | RYTM | -3.05 | 0.54 | 14.42 |
| 2026-07-28 | RYTM | -3.05 | 0.54 | 14.42 |
| 2026-07-29 | RYTM | -3.05 | 0.54 | 14.42 |
| 2026-07-30 | RYTM | -3.05 | 0.54 | 14.42 |
| 2026-07-31 | RYTM | -3.05 | 0.54 | 14.42 |
| 2026-08-03 | RYTM | -3.05 | 0.66 | 14.42 |
| 2026-08-04 | RYTM | -3.05 | 0.66 | 14.42 |
| 2026-08-05 | RYTM | -3.05 | 0.66 | 14.42 |
| 2026-08-06 | RYTM | -3.05 | 0.66 | 14.42 |
| 2026-08-07 | RYTM | -2.76 | 0.66 | 14.42 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.73
Avg. EPS Est. Current Quarter
-0.83
Avg. EPS Est. Next Quarter
-0.82
Insider Transactions
-2.76
Institutional Transactions
0.66
Beta
1.98
Average Sales Estimate Current Quarter
67
Average Sales Estimate Next Quarter
79
Fair Value
Quality Score
46
Growth Score
54
Sentiment Score
93
Actual DrawDown %
5.3
Max Drawdown 5-Year %
-78.1
Target Price
141.53
P/E
Forward P/E
PEG
P/S
36.66
P/B
77.27
P/Free Cash Flow
EPS
-3.14
Average EPS Est. Cur. Y
-3.26
EPS Next Y. (Est.)
-0.65
Target Price Estimates Raised
3
Target Price Estimates Lowered
Profit Margin
-95.71
Relative Volume
0.84
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
RYTM
Healthcare
$115.63
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
64.1
Range 1M
95.1%
Sup Dist
5.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
3.5%
EPS NY
77.8%
52W%
85.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+22.4% upside
Upside
+22.4%
Quality
46
RYTM — P/E HistoricalBiotechnology
Rhythm Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 414
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
RYTM
Latest News
—
Caricamento notizie per RYTM…
stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today
news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance
stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market
stock prices RYTM premarket after hours
ticker RYTM fair value insiders trading